Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Handbook of Experimental Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/978-3-642-17214-4_15PMID 21484579
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piragliatin (RO4389620), a novel glucokinase activator, lowers plasma glucose both in the postabsorptive state and after a glucose challenge in patients with type 2 diabetes mellitus: a mechanistic study.

  2010cited by this paper
• 2,3-Disubstituted acrylamides as potent glucokinase activators.

  2010cited by this paper
• Glucokinase-activating GCKR polymorphisms increase plasma levels of triglycerides and free fatty acids, but do not elevate cardiovascular risk in the Ludwigshafen Risk and Cardiovascular Health Study.

  2010cited by this paper
• Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).

  2010cited by this paper
• Large islets, beta-cell proliferation, and a glucokinase mutation.

  2010cited by this paper
• Glucose and aging control the quiescence period that follows pancreatic beta cell replication

  2010cited by this paper
• A small-molecule glucokinase activator lowers blood glucose in the sulfonylurea-desensitized rat.

  2010cited by this paper
• Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion

  2009cited by this paper
• Restoration of Hepatic Glucokinase Expression Corrects Hepatic Glucose Flux and Normalizes Plasma Glucose in Zucker Diabetic Fatty Rats

  2009cited by this paper
• Translating TCF7L2: from gene to function

  2009cited by this paper
• Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes

  2009cited by this paper
• Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials

  2009cited by this paper
• Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

  2009influential reference
• Benzamide derivatives as dual-action hypoglycemic agents that inhibit glycogen phosphorylase and activate glucokinase.

  2009cited by this paper
• Impact of small-molecule glucokinase activator on glucose metabolism and beta-cell mass.

  2009cited by this paper
• Combined analysis of 19 common validated type 2 diabetes susceptibility gene variants shows moderate discriminative value and no evidence of gene–gene interaction

  2009cited by this paper
• 3-Hydroxyacyl-coenzyme A dehydrogenase deficiency and hyperinsulinemic hypoglycemia: characterization of a novel mutation and severe dietary protein sensitivity.

  2009cited by this paper
• The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men

  2009cited by this paper
• Investigation of functionally liver selective glucokinase activators for the treatment of type 2 diabetes.

  2009cited by this paper
• Genetic dissection of type 2 diabetes.

  2009cited by this paper
• Binding kinetics of glucose and allosteric activators to human glucokinase reveal multiple conformational states.

  2009influential reference
• Extremes of Clinical and Enzymatic Phenotypes in Children With Hyperinsulinism Caused by Glucokinase Activating Mutations

  2009cited by this paper
• Assessing the potential of glucokinase activators in diabetes therapy

  2009influential reference
• The beta cell lesion in type 2 diabetes: there has to be a primary functional abnormality

  2009cited by this paper
• Update on mutations in glucokinase (GCK), which cause maturity‐onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia

  2009cited by this paper
• Genetic Disorders of the Pancreatic Beta Cell and Diabetes (Permanent Neonatal Diabetes and Maturity-Onset Diabetes of the Young)

  2008cited by this paper
• Glucokinase, the pancreatic glucose sensor, is not the gut glucose sensor

  2008cited by this paper
• Dual role of proapoptotic BAD in insulin secretion and beta cell survival

  2008influential reference
• Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence.

  2008cited by this paper
• Glucokinase activators as new type 2 diabetes therapeutic agents

  2008cited by this paper
• Pancreatic beta cell in health and disease

  2008cited by this paper
• Glucokinase in Glucose Homeostasis, Diabetes Mellitus, Hypoglycemia, and as Drug Receptor

  2008cited by this paper
• Glucose Sensing in L Cells: A Primary Cell Study

  2008cited by this paper
• Mutations in UCP2 in Congenital Hyperinsulinism Reveal a Role for Regulation of Insulin Secretion

  2008cited by this paper
• Genotype score in addition to common risk factors for prediction of type 2 diabetes.

  2008cited by this paper
• Ventromedial Hypothalamic Glucokinase Is an Important Mediator of the Counterregulatory Response to Insulin-Induced Hypoglycemia

  2008cited by this paper
• Crucial role of insulin receptor substrate‐2 in compensatory β‐cell hyperplasia in response to high fat diet–induced insulin resistance

  2008cited by this paper
• The emerging genetic architecture of type 2 diabetes.

  2008cited by this paper
• Clinical risk factors, DNA variants, and the development of type 2 diabetes.

  2008cited by this paper
• Glucokinase and molecular aspects of liver glycogen metabolism.

  2008cited by this paper
• Hyperinsulinism in infancy and childhood: when an insulin level is not always enough.

  2008influential reference
• Catalytic activation of human glucokinase by substrate binding – residue contacts involved in the binding of D‐glucose to the super‐open form and conformational transitions

  2008cited by this paper
• Glucokinase activators in diabetes management

  2008cited by this paper
• Glucose modulation of glucokinase activation by small molecules

  2008cited by this paper
• Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.

  2007cited by this paper
• Glucose-Dependent Modulation of Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator

  2007cited by this paper
• BCL-2 Family Proteins: Critical Checkpoints of Apoptotic Cell Death

  2007cited by this paper
• Insulin receptors in β-cells are critical for islet compensatory growth response to insulin resistance

  2007cited by this paper
• Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development

  2007cited by this paper
• When the usual insulin is just not enough

  2007cited by this paper
• Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

  2007cited by this paper
• Immunohistochemical Evidence for the Presence of Glucokinase in the Gonadotropes and Thyrotropes of the Anterior Pituitary Gland of Rat and Monkey

  2007cited by this paper
• A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium.

  2007cited by this paper
• Conformational transition pathway in the allosteric process of human glucokinase

  2006cited by this paper
• Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats

  2006cited by this paper
• A Glucose Sensor Role for Glucokinase in Anterior Pituitary Cells

  2006cited by this paper
• The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy.

  2006cited by this paper
• Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.

  2006cited by this paper
• From Clinicogenetic Studies of Maturity-Onset Diabetes of the Young to Unraveling Complex Mechanisms of Glucokinase Regulation

  2006cited by this paper
• Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis.

  2006cited by this paper
• The Free Fatty Acid Receptor GPR40 Generates Excitement in Pancreatic β-Cells

  2006cited by this paper
• Combining Information from Common Type 2 Diabetes Risk Polymorphisms Improves Disease Prediction

  2006cited by this paper
• Glucokinase regulatory protein is associated with mitochondria in hepatocytes

  2006cited by this paper
• The free fatty acid receptor GPR40 generates excitement in pancreatic beta-cells.

  2006cited by this paper
• An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism*

  2006cited by this paper
• Signaling Mechanisms Underlying the Release of Glucagon-Like Peptide 1

  2006cited by this paper
• Targeting glucokinase activation for the treatment of type 2 diabetes--a status review.

  2005influential reference
• A novel glucokinase activator modulates pancreatic islet and hepatocyte function.

  2005influential reference
• Glucokinase and glucose homeostasis: proven concepts and new ideas.

  2005cited by this paper
• Functional and molecular defects of pancreatic islets in human type 2 diabetes.

  2005cited by this paper
• Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation.

  2004cited by this paper
• Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells

  2004cited by this paper
• Hyperinsulinism in infancy: from basic science to clinical disease.

  2004influential reference
• Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase.

  2004influential reference
• Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects.

  2004cited by this paper
• Neuronal glucosensing: what do we know after 50 years?

  2004cited by this paper
• Glucokinase is an integral component of the insulin granules in glucose-responsive insulin secretory cells and does not translocate during glucose stimulation.

  2004cited by this paper
• Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators.

  2004cited by this paper
• The Hepatoportal Glucose Sensor

  2004cited by this paper
• Diabetes mellitus : a fundamental and clinical text

  2004cited by this paper
• Glucokinase and the Regulation of Blood Sugar

  2004cited by this paper
• Interaction of GK with the Bifunctional Enzyme 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (6PF2K/F26P2ase)

  2004cited by this paper
• Mouse Models of Altered Glucokinase Gene Expression

  2004cited by this paper
• Discovery and Actions of Glucokinase Activators

  2004cited by this paper
• Crystal Structure of Human Liver Glucokinase Bound to a Small Molecule Allosteric Activator

  2004cited by this paper
• Glucokinase in β-Cell Insulin-Secretory Granules

  2004cited by this paper
• The Hexokinase Gene Family

  2004cited by this paper
• Glucokinase and glycemic disease: from basics to novel therapeutics.

  2004cited by this paper
• Glucokinase: A Monomeric Enzyme with Positive Cooperativity

  2004cited by this paper
• Molecular Biology of Glucokinase Regulation

  2004cited by this paper
• The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

  2003cited by this paper
• Calcium: Regulation of cell death: the calcium–apoptosis link

  2003cited by this paper
• Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway.

  2003cited by this paper
• BAX and BAK Regulation of Endoplasmic Reticulum Ca2+: A Control Point for Apoptosis

  2003cited by this paper
• Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

  2003influential reference
• Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations.

  2003cited by this paper
• Identification of Fructose 6-Phosphate- and Fructose 1-Phosphate-binding Residues in the Regulatory Protein of Glucokinase*

  2002cited by this paper
• Genetic approaches to the molecular understanding of type 2 diabetes.

  2002cited by this paper
• Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators.

  2002cited by this paper
• The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy.

  2002cited by this paper

• Factors influencing the initial glycemic efficacy of dorzagliatin, a novel glucokinase activator, in type 2 diabetes

  2025cites this paper
• Conserved glucokinase regulation in zebrafish confirms therapeutic utility for pharmacologic modulation in diabetes

  2024cites this paper
• Recent drug development of dorzagliatin, a new glucokinase activator, with the potential to treat Type 2 diabetes: A review study

  2024cites this paper
• Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of SY-004, a Glucokinase Activator, in Healthy Chinese Adults: A Randomized, Phase Ia, Single-Ascending Dose Study.

  2022cites this paper
• Cholesterol Hydroxylating Cytochrome P450 46A1: From Mechanisms of Action to Clinical Applications

  2021cites this paper
• Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus

  2021cites this paper
• Elucidating the Glucokinase Activating Potentials of Naturally Occurring Prenylated Flavonoids: An Explicit Computational Approach

  2021cites this paper
• Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics.

  2020cites this paper
• Glucokinase Activators Based on N-Aryl-N′-Pyridin-2-Ylurea Derivatives

  2018cites this paper
• New hope for glucokinase activators in type 2 diabetes?

  2018cites this paper
• Reducing Glucokinase Activity Restores Endogenous Pulsatility and Enhances Insulin Secretion in Islets From db/db Mice.

  2018cites this paper
• Small molecules as activators in medicinal chemistry (2000–2016)

  2017cites this paper
• Inhibition of cholinergic potentiation of insulin secretion from pancreatic islets by chronic elevation of glucose and fatty acids: Protection by casein kinase 2 inhibitor

  2017cites this paper
• Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.

  2017cites this paper
• Structure-Activity Relationship of Azaindole-Based Glucokinase Activators.

  2016cites this paper
• QSAR Models Guided by Molecular Dynamics Applied to Human Glucokinase Activators

  2016cites this paper
• Investigational insulin secretagogues for type 2 diabetes

  2016cites this paper
• In type 1 diabetics, high-dose biotin may compensate for low hepatic insulin exposure, promoting a more normal expression of glycolytic and gluconeogenic enyzymes and thereby aiding glycemic control.

  2016cites this paper
• Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

  2015cites this paper
• The new biology of diabetes

  2015cites this paper
• Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development

  2015cites this paper
• Utilization of the Zucker Diabetic Fatty (ZDF) Rat Model for Investigating Hypoglycemia-related Toxicities

  2015influential citation
• Targets and Off-Targets of Kinase Inhibitors in Diabetes

  2015cites this paper
• Glucose homeostasis and the enteroinsular axis in the horse: a possible role in equine metabolic syndrome.

  2014cites this paper
• Analysis of the co-operative interaction between the allosterically regulated proteins GK and GKRP using tryptophan fluorescence

  2014cites this paper
• Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient.

  2014cites this paper
• Glucose homeostasis and the enteroinsular axis in the horse: a possible role in equine metabolic syndrome.

  2014cites this paper
• Discontinued in 2013: diabetic drugs

  2014cites this paper
• DMD060087 1926..1939

  2014cites this paper
• Recent updates on glucokinase activators for the treatment of type 2 diabetes mellitus.

  2014cites this paper
• Something old, something new and something very old: drugs for treating type 2 diabetes

  2014cites this paper
• Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator

  2014cites this paper
• Preclinical PK/PD modeling and human efficacious dose projection for a glucokinase activator in the treatment of diabetes

  2014cites this paper
• Molecular basis for the role of glucokinase regulatory protein as the allosteric switch for glucokinase

  2013cites this paper
• Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.

  2013cites this paper
• GKAs for diabetes therapy: why no clinically useful drug after two decades of trying?

  2013cites this paper
• Potent humanin analog increases glucose‐stimulated insulin secretion through enhanced metabolism in the β cell

  2013cites this paper
• Pharmacologic Stimulation of Cytochrome P450 46A1 and Cerebral Cholesterol Turnover in Mice*

  2013cites this paper
• Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans

  2013cites this paper
• Stimulation of cerebral cholesterol turnover 1 Pharmacologic stimulation of cytochrome P 450 46 A 1 and cerebral cholesterol turnover in mice

  2013cites this paper
• Making β Cells from Adult Cells Within the Pancreas

  2013cites this paper
• Latest research and development trends in non-insulin anti-diabetics

  2013cites this paper
• Antidiabetic agents: past, present and future.

  2013cites this paper
• Thermal stability of glucokinase (GK) as influenced by the substrate glucose, an allosteric glucokinase activator drug (GKA) and the osmolytes glycerol and urea.

  2012cites this paper
• Red carpeting the newer antidiabetics

  2012cites this paper
• Functional Characterization of MODY2 Mutations Highlights the Importance of the Fine-Tuning of Glucokinase and Its Role in Glucose Sensing

  2012cites this paper
• Human pancreatic glucokinase

  2012influential citation
• Glucokinase activation repairs defective bioenergetics of islets of Langerhans isolated from type 2 diabetics.

  2012cites this paper
• Regulation of hepatic glucose uptake and storage in vivo.

  2012cites this paper
• Glycemic variability in type 2 diabetes mellitus: oxidative stress and macrovascular complications.

  2012cites this paper
• Human pancreatic glucokinase. Structural and physico-chemical studies related to catalytic activation, kinetic cooperativity and GCK-diabetes.

  2012influential citation
• Repair of diverse diabetic defects of β‐cells in man and mouse by pharmacological glucokinase activation

  2012cites this paper
• Discovery and hit-to-lead optimization of novel allosteric glucokinase activators.

  2011cites this paper
• Mutational analysis of allosteric activation and inhibition of glucokinase.

  2011cites this paper